Baxter International Inc. (BAX)

5-star analyst Danielle Antalffy, of SVB Leerink, writes of Baxter, “[We] see BAX's underlying fundamentals -- accelerating sales growth, meaningful margin expansion -- as unchanged. One of the most meaningful datapoints in this quarter was 6% peritoneal dialysis patient growth… well ahead of the mid-single-digit long-term growth outlook for the Renal business that the Street is modeling. As the COVID pressures begin to lift, visibility into the long-term growth drivers should improve, and we would expect the shares to move meaningfully higher.”

And it doesn't hurt that Ray Dalio co-chief investment officer of the world's largest hedge fund, Bridgewater Associates just bought up 124,701 shares of the stock, a holding that is worth $9.73 million at current prices.